AZN Stock Recent News

AstraZeneca on Monday announced plans to invest $50 billion in its US operations by 2030, a sweeping commitment that includes building its largest-ever manufacturing facility in Virginia and expanding research and development across several states.

AstraZeneca PLC (LSE:AZN) has unveiled plans to invest $50 billion in the United States by 2030, marking its largest-ever commitment to a single country and signalling a major boost for domestic drug manufacturing and research. The centrepiece of the investment is a proposed multi-billion-dollar drug manufacturing facility in Virginia, which would be the company's largest single site worldwide.

AstraZeneca has become the latest pharma firm to announce a multi-billion investment in the U.S. The Anglo-Swedish biotech firm has committed to spend $50 billion by 2030.

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence in the company's largest market.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manu.

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy.

Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.

AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

AstraZeneca PLC (LSE:AZN) shares opened lower on Wednesday after a late-stage trial of its experimental treatment for AL amyloidosis failed to meet its primary target in the overall patient group. The CARES phase III study tested anselamimab, a drug designed to clear harmful protein deposits in organs.

AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of protein deposits in the body.